Invion Ltd has released a press release.
Appendix 4C and Quarterly Activities Report - March 2025
Filed with ASX ·
6ix hasn’t read this filing yet.
Earlier from Invion
- Share Purchase Agreement Termination and Tranche Repayment
- Completion Of Placement to Accelerate Clinical Programs
- Oesophageal Cancer Collaboration and Funding Agreement
- Activities Report and Appendix 4C
- Invion Doses First Patient in Phase I/II Skin Cancer Trial
Later from Invion
- Dosing of 1st Six Patients in Phase I/II Skin Cancer Trial
- Encouraging SRC Findings on Ph I/II Skin Cancer Trial
- Loyalty Option Entitlement Offer
- EQR Progresses Regional Tungsten Hub Strategy
- Underwritten Loyalty Option Entitlement Offer Prospectus
Follow Invion into a list and get an email when it puts out news.
Follow Invion